From October 10-13, 2024, Artechmed will showcase the Nationally Innovative Medical DeviceArtCryoTMCardiac Cryoablation SystemIn BeijingParticipated in“The 15th Biennial Academic Conference of the Chinese Society of Pacing and Electrophysiology (CSPE)”. This is ArtCryoTMThe debut at a major academic conference in China after receiving NMPA approval marks Artechmed's full launch of ArtCryo.TMClinical use and market promotion activities.
ArtCryoTMCardiac Cryoablation SystemIncludingArtFreezerTMCryoballoon Catheter、ArtGlacierTMCryogenic Ablation System、ArtCircleTMCircular Mapping Catheter、ArtDeliverTMAdjustable Bend Sheath, and have now all been approved for marketing.Within the industry“Maximum Size"The cryoballoon catheter, in conjunction with“Intelligent Temperature Control”And“Adjustable Cooling Capacity”Functional Cryoablation Device, ArtCryoTMWith better safety and higher efficacy, enabling the true realization of cryoablation surgery for atrial fibrillation.“BigInstrument has a limit,WisdomArtechmed”。
Except ArtCryoTMIn addition, Artechmed will also launchCardiac Pulse Field Ablation System (PFA)AndHeartAlcohol Ablation System (VOM)Products, etc., accelerate the establishment of a new atrial fibrillation ablation platform, providing moreSafety、EffectiveAndSimpleDiagnostic and treatment solutions.
About CSPE Academic Biennial ConferenceSince its establishment in 1994, the biennial conference of the Chinese Medical Association's Branch of Electrocardiology and Pacing has been successfully held for 15 consecutive sessions. Over the years, with the strong support and active participation of numerous academic colleagues and organizations, it has provided a comprehensive platform for the continuous integration and development of rapidly advancing research, diagnostic technologies, and clinical practices in arrhythmia, becoming one of the most influential academic events in the field of arrhythmia in China and even the Asia-Pacific region.Artechmed was founded in 2017, with its headquarters located in the International Medical Park of Zhangjiang Science City, Shanghai, focusing on innovative solutions for cardiac electrophysiology diagnosis and treatment. The company has dual product technology platforms in Cryoballoon Ablation (CBA) and Pulsed Field Ablation (PFA), along with dozens of core independent intellectual property rights. The key team members all have extensive experience working in well-known medical device companies and possess rich expertise in the research and development, production, clinical development, commercialization, and company operations of products in the fields of electrophysiological diagnosis and treatment, cardiovascular and cerebrovascular interventions, cryoablation, and active medical devices.
